2009
DOI: 10.1016/j.jhep.2008.07.038
|View full text |Cite
|
Sign up to set email alerts
|

The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

7
39
0

Year Published

2011
2011
2016
2016

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 42 publications
(46 citation statements)
references
References 34 publications
7
39
0
Order By: Relevance
“…The incidence rate of rtL80I mutation (86.36%; 19/22) was also higher than that of rtL80V (13.67%; 3/22). These results were congruent with those of previous reports [27,28]. These data suggest that some of the amino acid positions in the HBV RT region of NAs-treated patients prefer certain mutational patterns.…”
Section: Discussionsupporting
confidence: 92%
“…The incidence rate of rtL80I mutation (86.36%; 19/22) was also higher than that of rtL80V (13.67%; 3/22). These results were congruent with those of previous reports [27,28]. These data suggest that some of the amino acid positions in the HBV RT region of NAs-treated patients prefer certain mutational patterns.…”
Section: Discussionsupporting
confidence: 92%
“…Selecting effective therapeutic plans is critically needed due to the reported association of genotype D with high risk of severe liver disease, recurrence, and fulminant hepatitis [2,7]. Fortunately, genotype D influence on driving viral evolution leading to the emergence of resistance mutations under nucleos(t)ide analogues pressure is relatively low [5,14]. Thus considering HBV genotype is crucial for therapeutic decision making whether by interferon or nucleos(t)ide analogues [8].…”
Section: Discussionmentioning
confidence: 99%
“…Hence investigating resistance mutations beforehand is recommended for efficient drug prescription. Moreover, monitoring drug-resistant mutants during nucleos(t)ide analogues treatment is necessary to ensure early detection of potentially emerging mutations before considerable serum viral load increase in the patient occurs [3,5,15]. This necessity is underscored by our findings of detecting multiple resistance mutations in LMV/ADV-treated patients whose therapeutic plans were continued due to lack of awareness of the critical necessity of timely rescue therapy, and hence were at high risk of mutant selection that led to viral breakthrough, and might lead to hepatitis flare, hepatic decompensation and death [3,15].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations